BLUEROCK
Live / Allowed — Fifth extension granted (statement of use) (as of 17 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 13 Jul 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97501359
- Mark type
- Word mark
- Filed
- 13 Jul 2022
- Published for opposition
- 19 Sept 2023
- Attorney of record
- Phillip Barengolts
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use; genetic material being cells and biological tissue cultures for medical or clinical use; cell therapy and genetic medicine-based pharmaceutical and therapeutic pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; pharmaceutical and therapeutic pharmaceutical preparations in the nature of cells for human use for treating Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through cell therapy or gene therapy; cell therapy and genetic medicine-based pharmaceutical preparations for the treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases through gene therapy and cell therapy
- Class 044 — Medical, beauty and agricultural services: Medical treatment of Parkinson's disease, cancer, cardiovascular disease, ophthalmological diseases, autoimmune disorders, neurological disorders, lysosomal disorders, central nervous system diseases, gastrointestinal disorders, dermatological disorders, inflammatory diseases, metabolic disorders, respiratory diseases, and endocrine diseases; collection and preservation of human biological tissue, blood and cells for medical diagnostic testing purposes; medical diagnostic testing, monitoring and reporting services
Owner
- BlueRock Therapeutics LP, Cambridge, MA, US
- BlueRock Therapeutics LP, Cambridge, MA, US
Prior registrations
Prosecution history
- 18 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Sept 2026 — SOU EXTENSION 5 GRANTED
- 21 Apr 2026 — SOU EXTENSION 5 FILED
- 17 Aug 2026 — CORRECTED NOA E-MAILED
- 17 Aug 2026 — DIVISIONAL PROCESSING COMPLETE
- 21 Apr 2026 — DIVISIONAL REQUEST RECEIVED
- 14 Aug 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 21 Apr 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 21 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 04 Nov 2025 — SOU EXTENSION 4 GRANTED
- 04 Nov 2025 — SOU EXTENSION 4 FILED
- 04 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 06 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 May 2025 — SOU EXTENSION 3 GRANTED